Table 2.
Treatment Received by Patients with Metastatic Colorectal Cancer in the High c-Cbl and Low c-Cbl Groups
| Treatment | High c-Cbl (n = 38) | Low c-Cbl (n = 34) | P value |
|---|---|---|---|
| Received surgery, % | 86.84 | 67.65 | 0.05 |
| Received chemotherapy, % | 81.58 | 70.59 | 0.27 |
| First-line chemotherapy, % | |||
| Chemotherapy regimen received | |||
| FOLFOX/CAPEOX, % | 80.65 | 83.33 | 0.80 |
| FOLFIRI/CAPEIRI, % | 3.23 | 12.50 | 0.19 |
| Biologics received | |||
| Bevacizumab | 54.84 | 70.83 | 0.23 |
| EGFR inhibitor | 12.90 | 0.00 | 0.07 |
| Mean cycles received, n | 7.39 | 7.58 | 0.87 |
| Response to first-line chemotherapy, AU | |||
| ORR | 51.61 | 54.17 | 0.85 |
| PR | 45.16 | 33.33 | 0.37 |
| CR | 6.45 | 20.83 | 0.11 |
AU, arbitrary units; CAPEIRI, capecitabine, irinotecan; CAPEOX, capecitabine, oxaliplatin; c-Cbl, Casitas B-lineage lymphoma; CR, complete response; FOLFIRI, 5-fluorouracil, leucovorin, irinotecan; FOLFOX, 5-fluorouracil, leucovorin, oxaliplatin; ORR, overall response rate; PR, partial response.